on Champions Oncology, Inc. (NASDAQ:CSBR)
Champions Oncology Launches Comprehensive Radiopharmaceutical Platform
Champions Oncology, a leader in translational oncology research, announced the commercial launch of its new radiopharmaceutical services platform. This development follows the expansion of their radioactive materials license and the successful screening of over thirty PDX models. This advancement allows for integrated workflows, combining various studies using an extensive range of isotopes.
The platform is distinguished by its robust bank of patient-derived xenograft (PDX) tumor models, offering drug developers the ability to assess radiolabeled agents effectively. The updated license now supports ten key isotopes, facilitating diverse study designs such as radioligand therapy and antibody radionuclide conjugates.
The initiative aims to accelerate critical drug development decisions with data reflecting authentic tumor biology, supporting biopharma partners in preclinical evaluations.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Champions Oncology, Inc. news